Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Dermatologic 1

Conditions

Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Gastric Cancer With Liver Metastases 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Immunotherapy × 30 days × Clear all
NCT06731413 2026-06-02

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Virginia Commonwealth University

Phase 2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT07162506 2026-05-29

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT07602140 2026-05-22

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

Shandong Provincial Hospital

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Gastric Cancer With Liver Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡